Latest News for: edema

Edit

Opthea Announces Publication in Diabetic Macular Edema

Nasdaq Globe Newswire 07 Jan 2025
Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME ... .
Edit

Opthea Announces Publication in Diabetic Macular Edema Form 6 K (Opthea Limited)

Public Technologies 07 Jan 2025
Opthea Announces Publication in Diabetic Macular Edema ... Diabetic macular edema is the leading cause of central vision loss in people living with diabetes ... (wet AMD) and diabetic macular edema (DME).
Edit

Do your indoor plants have edema? We'll tell you how to treat it.

Beaumont Enterprise 29 Dec 2024
Bringing your plants inside for the winter can cause conditions that lead to edema ....
Edit

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion (Decibel Therapeutics Inc)

Public Technologies 17 Dec 2024
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion.
Edit

Diabetic Macular Edema Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 27 Nov 2024
"Diabetic Macular Edema Market". Diabetic Macular Edema Companies are Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab.
Edit

Emmecell Announces Positive Topline Results from Randomized, Double-masked Trial of Groundbreaking Non-surgical Cell Therapy for Corneal Edema

PR Newswire 18 Nov 2024
multi-center Phase 1 extension study evaluating EO2002, a non-surgical cell therapy for corneal edema ... us closer to providing a transformative, non-surgical treatment for patients with corneal edema.".
Edit

Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema (Santen Pharmaceutical Co Ltd)

Public Technologies 07 Nov 2024
) Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema.
Edit

EyePoint Pharmaceuticals Announces Positive Interim 16 Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYUTM for Diabetic Macular Edema Form 8 K (EyePoint Pharmaceuticals Inc)

Public Technologies 28 Oct 2024
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYUTM for Diabetic Macular Edema ... macular edema (DME) ... About Diabetic Macular Edema.
Edit

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema ...

Nasdaq Globe Newswire 21 Oct 2024
ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq ... .
Edit

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees (Oculis Holding AG)

Public Technologies 21 Oct 2024
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees ... About the Phase 3 DIAMOND Program of OCS-01 in Diabetic Macular Edema ... About Diabetic Macular Edema (DME).
Edit

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

The Joplin Globe 19 Oct 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 18, 2024-- ... .
Edit

Long-term efficacy and safety profile of Eylea™ 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years (Bayer AG)

Public Technologies 19 Oct 2024
). The text version of this document is not available ... Disclaimer ... (noodl. 120394868) .
Edit

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First Of Its Kind Study (Roche Holding AG)

Public Technologies 18 Oct 2024
). The text version of this document is not available ... Disclaimer ... (noodl. 120391955) .
Edit

Roche’S Vabysmo Improved Vision In Underrepresented Populations With Diabetic Macular Edema (DME) In A First-Of-Its-Kind Study

MENA FN 18 Oct 2024
(MENAFN - GlobeNewsWire - Nasdaq) The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with ... .
Edit

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First Of Its Kind Study (Genentech Inc)

Public Technologies 18 Oct 2024
... by injection into the eye, used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).

Article Search

tools

Most Viewed

×
×
×
×